Management Team

  • tb_mon.jpg

    Michael Oredsson President and CEO

    Degree in International Business Administration from Lund University. Born 1960. Lives in Beddingestrand, Sweden. Employed since 2013. He was CEO of Probi AB 2007-2013. Former CEO of Biosignal in Australia, 2002-2007, and Nutripharma in Norway, 1999-2001. Before that he was responsible for building up Pharmacia’s OTC product division in Australia. He also held senior marketing positions at Nestlé and Mars Inc in Sweden, Germany and France.

    Shareholding: 913,035

    Options: Employee options: 18,719

  • tb_bfr.jpg

    Björn Frendéus Chief Scientific Officer

    Doctor of Immunology. Born 1973. Lives in Landskrona, Sweden. Employed since 2001. Graduated from the Swedish Foundation for Strategic Research funded Biomedicine programmes within the Infection & Vaccinology programme in 2001. Visiting Professor at University of Southampton.

    Shareholding: 317,151 (own and affiliated holdings)

    Options: Employee options: 6,000

  • no_picture.jpg

    Kristoffer Rudenholm Hansson Vice President, Technical Operations

    Master of Science in Chemical engineering. Born 1974. Lives in Malmö Sweden. Employed since 2016 and responsible for process development and production of antibodies for clinical studies. He has more than 15 years’ experience from managing manufacturing of antibodies and other proteins for clinical use. Kristoffer has held a numerous positions within CMC Biologics A/S, DAKO A/S and Symphogen A/S.

    Shareholding: 491,628 (whereof 148,176 in Sw. kapitalförsäkring)

    Options: Stock options: 50,000

  • tb_atw.jpg

    Anna Wickenberg Vice President, Clinical Development

    PhD in Medical Sciences, Immunology, and MSc in Molecular Biology. Born in 1974. Lives in Lund, Sweden. Employed since 2015 and responsible for the clinical development. She has 15 years of experience of leading clinical development projects from various positions at Teva Pharmaceuticals, NeuroSearch, and AstraZeneca. Most recently, Anna was responsible for the clinical development of new chemical entities in an orphan indication within CNS at Teva.

    Shareholding: 231 348

    Options: -